Caleb Pharmaceuticals, Inc.

DUBLIN--( BUSINESS WIRE )--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027. The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR. Select Competitors (Total 41 Featured) - Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E) Impact of Covid-19 and a Looming Global Recession Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv